{"id":"NCT03928743","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-25","primaryCompletion":"2021-09-03","completion":"2022-08-08","firstPosted":"2019-04-26","resultsPosted":"2024-10-10","lastUpdate":"2024-10-10"},"enrollment":332,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ankylosing Spondylitis"],"interventions":[{"type":"DRUG","name":"Bimekizumab","otherNames":["BKZ","UCB4940"]},{"type":"OTHER","name":"Placebo","otherNames":["PBO"]}],"arms":[{"label":"Bimekizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).","primaryOutcome":{"measure":"Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo (up to Week 16)","deltaMin":22.5,"sd":null},{"arm":"Bimekizumab 160 mg Q4W (up to Week 16)","deltaMin":44.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":83,"countries":["United States","Belgium","Bulgaria","China","Czechia","France","Germany","Hungary","Japan","Netherlands","Poland","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["36649967","38599650","38834351","40194794","39406403","39133438","37793792"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":111},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Oral Candidiasis","Diarrhoea"]}}